

July 6, 2026

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G - Block
Bandra –Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel (SMP)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy, with effect from August 1, 2026 and Mr. Amay Ashok Pandey as Director – Oncology Business Unit with effect from September 1, 2026.

Also, further to our communication dated March 25, 2024, we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the promotion of Mr. Vinay Sharma to Director - Rare Diseases Business Unit from Business Unit Head - Rare Disease Business Unit, effective August 1, 2026.

These being SMP positions in terms of the SEBI Listing Regulations, please find the details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking you,

For AstraZeneca Pharma India Limited

Tanya Sanish
Company Secretary & Compliance Officer

Annexure - A

| Sl. No. | Particulars | Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy | Mr. Vinay Sharma as Director - Rare Diseases Business Unit | Mr. Amay Ashok Pandey as Director – Oncology Business Unit |
|----------------|---|--|--|---|
| 1 | Reason for change viz. appointment, resignation, removal, death or otherwise; | Appointment as SMP | Change in designation of SMP | Appointment as SMP |
| 2 | Date of appointment/cessation (as applicable) and term of appointment | Effective August 1, 2026 Term of appointment – Full – time employment | Effective August 1, 2026 Term of appointment – Full – time employment | Effective September 1, 2026 Term – Full – time employment |
| 3 | Brief Profile | <p>Mr. Mihir Parikh is a biopharmaceutical commercial leader with over 15 years of experience across oncology marketing, sales leadership, product launches, market access, and commercial strategy in India and international markets.</p> <p>He is currently the Breast Cancer Franchise Lead at AstraZeneca, where he rejoined the organization in July 2025. He is responsible for the commercial strategy and growth of ENHERTU, including expansion of the public channel,</p> | <p>Mr. Vinay Sharma is a seasoned healthcare business leader with demonstrated expertise in strategic launches, franchise building, and driving high-growth outcomes across specialty therapy markets. Since assuming the role of Rare Disease Business Unit Head in July 2024, he has played a pivotal role in shaping the franchise’s bold ambition and brand strategy, developing its strategic roadmap, and successfully launching new assets in India. His contributions have been recognized through Asia Area Growth & TA</p> | <p>Mr. Amay Ashok Pandey is a seasoned oncology commercial leader with nearly a decade of experience at AstraZeneca and over 18 years of experience in the pharmaceutical industry. He currently serves as Head of Sales & Operations – Oncology (International Assignment) based in Jakarta, where he is responsible for leading commercial strategy and driving execution for the Oncology Business Unit.</p> <p>He brings deep expertise across oncology portfolios, underpinned</p> |

| | | | | |
|--|--|---|---|--|
| | | <p>launch of new indications, and pre-launch planning for Datverzo and Etcamah within the breast cancer portfolio.</p> <p>Over the course of his career, he has led multiple phases of the product lifecycle, including market shaping, launch execution, portfolio growth, and loss of exclusivity planning. During his earlier tenure at AstraZeneca, he led the commercial launch of a breast cancer therapy and managed sales operations across South and West India. He also contributed to regional initiatives across Asia Area markets, supporting launch readiness, scientific engagement, and market access.</p> <p>Prior to AstraZeneca, he has held commercial leadership roles at Novartis and Roche across therapeutic areas including breast cancer, lung cancer, regenerative medicine, hematology, immuno-oncology, and specialty care. His experience includes commercial</p> | <p>Leadership Award 2025 and the Global Alexion Excellence Award 2025.</p> <p>Prior to this, he was a member of the Country Leadership Team at AstraZeneca Philippines for over three years, where he led the Respiratory & Immunology Business Unit. In this role, he delivered strong revenue growth and successfully launched new assets such as Breztri and Saphnelo.</p> <p>Earlier, as Head of Marketing – Biopharmaceuticals AZ Philippines, he oversaw the CVRM, Respiratory, and Immunology portfolios, driving best-in-class screening initiatives across the Asia Area and driving highest growth for Forxiga Family.</p> <p>During his earlier seven-year tenure at the Company, Vinay held progressive leadership roles of increasing responsibility. He was instrumental in establishing the severe asthma franchise in preparation for the launch of Fasenra, and led the highly</p> | <p>by strong capabilities in strategic marketing, sales leadership, and shaping eco-system through cross-functional collaboration. Throughout his tenure at AstraZeneca, Amay has held several key leadership roles, including Franchise Head – Women’s Cancer and Senior Marketing Manager, where he has consistently delivered sustainable business growth while building and leading high-performing teams.</p> <p>Prior to joining AstraZeneca, Amay held progressive leadership roles at leading multinational organizations, including Roche, GlaxoSmithKline, Janssen (Johnson & Johnson), and Zydus. During this time, he successfully led multiple oncology product launches, developed and executed effective go-to-market strategies, and drove market share expansion across diverse therapeutic portfolios.</p> <p>Amay is recognized for bridging strategy and execution, with a</p> |
|--|--|---|---|--|

| | | | | |
|--|--|--|---|---|
| | | <p>strategy, sales leadership, market access, diagnostic ecosystem development, and cross-functional business transformation.</p> <p>Mihir is an alumnus of the Indian School of Business and Rutgers University, with an academic background in engineering and management.</p> | <p>successful launch of Forxiga, which was recognized as the Best Pharma Launch in India for the year 2016.</p> <p>These accomplishments also earned him multiple Marketing Excellence Awards and Asia Area Growth Awards.</p> <p>Before joining AstraZeneca, Vinay spent nearly a decade at Novartis India, where he held several Sales and Senior marketing roles. Among his notable achievements was the launch of Galvus (Vildagliptin), which went on to become the number one DPP-4 brand in the country, despite being the second entrant in the market.</p> <p>With around two decades of experience in the pharmaceutical industry, academically He holds a Bachelor's degree in Pharmacy and an Executive MBA from the Indian Institute of Management Calcutta.</p> | <p>strong focus on ecosystem shaping mobilizing multi-stakeholder partnerships across the healthcare landscape to enhance access, drive innovation adoption, and deliver sustained commercial and patient impact in complex Oncology markets.</p> |
|--|--|--|---|---|

| | | | | |
|---|---|----------------|----------------|----------------|
| 4 | Disclosure of relationships between directors | Not Applicable | Not Applicable | Not Applicable |
|---|---|----------------|----------------|----------------|

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
 P. B. No. 4525, Block N1, 12th Floor,
 Manyata Embassy Business Park,
 Rachenahalli, Outer Ring Road,
 Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
 12th Mile on Bellary Road
 Venkatala, Kattigenahalli Village
 Yelahanka
 Bangalore - 560 063
 INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
 +91 80 6774 9628